CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Translate Bio, a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases, today announced the appointment of Daniella Beckman to its board of directors, effective immediately. Ms. Beckman will also serve as chairperson of the board’s audit committee.
“Daniella joins our board of directors at an exciting time for Translate Bio,” said Ronald Renaud, chief executive officer, Translate Bio. “Her financial and operational expertise will be vital as we continue to build the company and bring our first product candidate into the clinic for the treatment of cystic fibrosis in early 2018.”
“I am thrilled to join the Translate Bio board of directors at such a pivotal time for the organization,” said Ms. Beckman. “I look forward to supporting the Company and being a part of a dedicated team focused on developing innovative products for genetic diseases.”
Ms. Beckman has over 15 years of financial and operational experience working with private and publicly traded biotechnology companies. She currently provides consulting and interim chief financial officer services for early-stage biotechnology companies, which recently has included Tango Therapeutics and Neon Therapeutics. With strategic and operational expertise, Ms. Beckman focuses on building financial infrastructure and leading financial functions, including strategic financial planning. Previously, Ms. Beckman was the chief financial officer of Idenix Pharmaceuticals until it was acquired by Merck in 2014. At Idenix, she oversaw finance, treasury, capital raises, investor relations and IT. Prior to the CFO role, Ms. Beckman also served as Idenix’s corporate controller. Earlier in her career, she held various finance positions at Coley Pharmaceuticals, Biogen Idec and PricewaterhouseCoopers. Ms. Beckman holds a B.A. in business administration/accounting from Boston University. She is also a certified public accountant in Massachusetts.
Translate Bio’s lead development programs in cystic fibrosis and OTC deficiency are expected to begin Phase 1 clinical testing in early 2018 and mid-2018, respectively.
About Translate Bio
Translate Bio is a leading biotechnology company focused on pioneering the translation of RNA science into therapeutics promoting healthy gene expression in people living with debilitating genetic diseases. The company’s RNA platforms for powering endogenous therapeutic protein production is applicable to a broad range of diseases including rare diseases of the liver, lung and central nervous system (CNS). For more information about the company, please visit www.translate.bio.
View source version on businesswire.com: http://www.businesswire.com/news/home/20171004005121/en/
Maura Gavaghan, 857-242-7789
Source: Translate Bio